<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39381050</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2397-1991</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of scleroderma and related disorders</Title><ISOAbbreviation>J Scleroderma Relat Disord</ISOAbbreviation></Journal><ArticleTitle>Changes in work and adequacy of financial resources during COVID-19 among people with systemic sclerosis: A Scleroderma Patient-centered Intervention Network study.</ArticleTitle><Pagination><StartPage>242</StartPage><EndPage>247</EndPage><MedlinePgn>242-247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/23971983241262655</ELocationID><Abstract><AbstractText Label="INTRODUCTION/OBJECTIVE" NlmCategory="UNASSIGNED">We investigated (1) work status changes during COVID-19, (2) financial resource adequacy, (3) preferences for work requirements (e.g. remote, workplace, mixed) and (4) work requirements versus preferences, among people with systemic sclerosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This was a cross-sectional study of participants in the Scleroderma Patient-centered Intervention Network COVID-19 Cohort, which enrolled participants from the ongoing Scleroderma Patient-centered Intervention Network Cohort and externally in April 2020. In August 2022, participants completed questions on work status, financial well-being using the Consumer Financial Protection Bureau Financial Well-Being Scale, work requirements and work requirement preferences.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 298 participants with systemic sclerosis were included. Mean age was 58.6 years (SD = 11.4). There were 101 (34%) participants working at the start of the pandemic and still working in August 2022, 179 (60%) not working at the start of the pandemic and still not working, 10 (3%) who stopped working after April 2020 and 8 (3%) who started working. Mean financial well-being did not change from April 2020 to August 2022 (difference: 0.2 points; 95% confidence interval: -1.1 to 0.7). Working participants (N = 109) preferred flexible work requirements (N = 34, 31%) or working entirely remotely (N = 32, 29%), but most were required to work entirely at a workplace (N = 35, 32%) or combined workplace and remotely with a fixed schedule (N = 31, 28%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Work status and financial well-being did not change substantively among people with systemic sclerosis during the pandemic. Flexible work policies may support people with systemic sclerosis to work.</AbstractText><CopyrightInformation>© The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nassar</LastName><ForeName>Elsa-Lynn</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrier</LastName><ForeName>Marie-Eve</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwakkenbos</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology, Behavioural Science Institute, Radboud University, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of IQ Health, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Mindfulness, Department of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virgili-Gervais</LastName><ForeName>Gabrielle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Susan J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuné</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ottawa Scleroderma Support Group, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gietzen</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Scleroderma Foundation, Tri-State Chapter, Binghamton, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gottesman</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Scleroderma Foundation, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillot</LastName><ForeName>Geneviève</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sclérodermie Québec, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Marie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6718-2468</Identifier><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrie-Jones</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Scleroderma Australia, Melton, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scleroderma Victoria, Fitzroy, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Scleroderma Patient-centered Intervention Network, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malcarne</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Psychology, San Diego State University, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>San Diego State University and University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayes</LastName><ForeName>Maureen D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>University of Texas McGovern School of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patten</LastName><ForeName>Scott B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Scleroderma Atlantic, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauvé</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Scleroderma Society of Ontario, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scleroderma Canada, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varga</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Welling</LastName><ForeName>Joep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NVLE Dutch patient organization for systemic autoimmune diseases, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojeck</LastName><ForeName>Robyn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The University of Rhode Island, Kingston, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouthon</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP-CUP, Hôpital Cochin, Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benedetti</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Research Institute of the McGill University Health Centre, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Respiratory Epidemiology and Clinical Research Unit, McGill University Health Centre, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thombs</LastName><ForeName>Brett D</ForeName><Initials>BD</Initials><Identifier Source="ORCID">0000-0002-5644-8432</Identifier><AffiliationInfo><Affiliation>Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SPIN Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Scleroderma Relat Disord</MedlineTA><NlmUniqueID>101685427</NlmUniqueID><ISSNLinking>2397-1983</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">employment</Keyword><Keyword MajorTopicYN="N">financial well-being</Keyword><Keyword MajorTopicYN="N">scleroderma</Keyword><Keyword MajorTopicYN="N">systemic sclerosis</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381050</ArticleId><ArticleId IdType="pmc">PMC11457775</ArticleId><ArticleId IdType="doi">10.1177/23971983241262655</ArticleId><ArticleId IdType="pii">10.1177_23971983241262655</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Poole JL, Anwar S, Mendelson C, et al.. Workplace barriers encountered by employed persons with systemic sclerosis. Work Read Mass 2016; 55(4): 923–929.</Citation><ArticleIdList><ArticleId IdType="pubmed">28059813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandqvist G, Hesselstrand R, Scheja A, et al.. Managing work life with systemic sclerosis. Rheumatol Oxf Engl 2012; 51(2): 319–323.</Citation><ArticleIdList><ArticleId IdType="pubmed">22019802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Kwakkenbos L, Henry RS, et al.. Validation of the COVID-19 fears questionnaires for chronic medical conditions: a Scleroderma Patient-centered Intervention Network COVID-19 cohort study. J Psychosom Res 2020; 139: 110271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543945</ArticleId><ArticleId IdType="pubmed">33096402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausmann JS, Kennedy K, Simard JF, et al.. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol 2021; 3(10): e707–e714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298011</ArticleId><ArticleId IdType="pubmed">34316727</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwakkenbos L, Jewett LR, Baron M, et al.. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open 2013; 3(8): e003563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3740254</ArticleId><ArticleId IdType="pubmed">23929922</ArticleId></ArticleIdList></Reference><Reference><Citation>Thombs BD, Jewett LR, Assassi S, et al.. New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). Clin Exp Rheumatol 2012; 30(2 Suppl. 71): S23–S29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3925434</ArticleId><ArticleId IdType="pubmed">22244687</ArticleId></ArticleIdList></Reference><Reference><Citation>
Scleroderma Patient-centered Intervention Network (SPIN). Cohort, https://www.spinsclero.com/en/cohort (accessed 29 April 2024).</Citation></Reference><Reference><Citation>van den Hoogen F, Khanna D, Fransen J, et al.. 2013 classification criteria for systemic sclerosis: an American college of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65(11): 2737–2747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930146</ArticleId><ArticleId IdType="pubmed">24122180</ArticleId></ArticleIdList></Reference><Reference><Citation>
Consumer Financial Protection Bureau. Measuring financial well-being: a guide to using the CFPB financial well-being scale, https://www.consumerfinance.gov/data-research/research-reports/financial-well-being-scale/ (accessed 4 March 2024).</Citation></Reference><Reference><Citation>Agresti A, Coull BA. Approximate is better than ‘exact’ for interval estimation of binomial proportions. Am Stat 1998; 52(2): 119–126.</Citation></Reference><Reference><Citation>Lee JJY, Gignac MAM, Johnson SR. Employment outcomes in systemic sclerosis. Best Pract Res Clin Rheumatol 2021; 35(3): 101667.</Citation><ArticleIdList><ArticleId IdType="pubmed">33714678</ArticleId></ArticleIdList></Reference><Reference><Citation>Thombs BD, Kwakkenbos L, Henry RS, et al.. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: a Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. J Psychosom Res 2020; 139: 110262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7532799</ArticleId><ArticleId IdType="pubmed">33070043</ArticleId></ArticleIdList></Reference><Reference><Citation>
Scleroderma Australia. Scleroderma and the workplace, https://www.sclerodermaaustralia.com.au/wp-content/uploads/2023/10/Scleroderma-Aus-Scleroderma-and-the-Workplace.pdf, (accessed 29 April 2024).</Citation></Reference><Reference><Citation>Joyce K, Pabayo R, Critchley JA, et al.. Flexible working conditions and their effects on employee health and wellbeing. Cochrane Database Syst Rev 2010; 2010(2): CD008009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175959</ArticleId><ArticleId IdType="pubmed">20166100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray TK, Pana-Cryan R. Work flexibility and work-related well-being. Int J Environ Res Public Health 2021; 18(6): 3254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8004082</ArticleId><ArticleId IdType="pubmed">33801122</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrisroe K, Huq M, Stevens W, et al.. Determinants of unemployment amongst Australian systemic sclerosis patients: results from a multicentre cohort study. Clin Exp Rheumatol 2016; 34(5 Suppl. 100): 79–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27463997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>